FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation By Ogkologos - October 30, 2025 248 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR After a Breast Cancer Diagnosis, Men May Be More Likely to... October 2, 2019 FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous... March 18, 2026 FDA Approves Pafolacianine for Identifying Malignant Ovarian Cancer Lesions December 16, 2021 Higher Risk of Heart Failure Seen in Some Cancers March 26, 2018 Load more HOT NEWS Pembrolizumab Now Second Immunotherapy Approved to Treat Merkel Cell Carcinoma EMA Recommends Extension of Indications for Nivolumab Longest Follow-Up of CAR T-Cell Therapy in Mantle Cell Lymphoma Points... EU Cancer Mission and Partners Launch First Cancer Mission Forum for...
